Cheri Vachtsevanos, MD
Internal Medicine · Gainesville, GANPI 1609844067
Payments from drug & device makers
Across 315 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$857
- Amgen$577
- Lilly USA, LLC$466
- Boehringer Ingelheim$444
- Pfizer$432
- Amarin Pharma, Inc.$306
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,449100%
- Education$60%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $857 |
| Amgen(2 entities) | 36 | $577 |
| Lilly USA, LLC | 29 | $466 |
| Boehringer Ingelheim | 25 | $444 |
| Pfizer | 23 | $432 |
| Amarin Pharma, Inc. | 20 | $306 |
| AbbVie | 19 | $304 |
| Novo Nordisk | 18 | $264 |
| Vanda Pharmaceuticals Inc. | 11 | $256 |
| Merck | 14 | $225 |
| Johnson & Johnson | 10 | $159 |
| Abbott | 7 | $141 |
| Bayer | 7 | $133 |
| Catalyst Orthoscience | 1 | $112 |
| Exact Sciences | 6 | $105 |
| GSK | 3 | $67 |
| Astellas Pharma US Inc | 3 | $64 |
| Edwards Lifesciences | 2 | $58 |
| Radius Health, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Medtronic | 1 | $48 |
| Phathom Pharmaceuticals, Inc. | 4 | $45 |
| Philips North America LLC | 1 | $29 |
| Saluda Medical Americas, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Triad Life Sciences Inc. | 1 | $19 |
| Globus Medical | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Covis Pharma GmbH | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Linus Health, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,468 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 149 | $171,986 |
| EliquisApixaban | 118 | $117,034 |
| JardianceEmpagliflozin | 103 | $96,274 |
| OzempicSemaglutide | 85 | $81,075 |
| FarxigaDapagliflozin Propanediol | 48 | $52,432 |
| TrulicityDulaglutide | 33 | $47,672 |
| ProliaDenosumab | 25 | $43,248 |
| XareltoRivaroxaban | 33 | $43,118 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $32,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $31,083 |
| Repatha SureclickEvolocumab | 20 | $26,095 |
| TradjentaLinagliptin | 23 | $21,981 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $20,561 |
| MyrbetriqMirabegron | 22 | $17,530 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $13,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $466 | $219,657182 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $444 | $125,177139 claims |
| PfizerEliquis, Premarin | $432 | $121,555137 claims |
| Novo NordiskOzempic | $264 | $81,07585 claims |
| AstraZenecaFarxiga | $857 | $52,43248 claims |
| AmgenProlia | $577 | $43,24825 claims |
| Johnson & JohnsonXarelto | $159 | $43,11833 claims |
| MerckJanumet, Januvia | $225 | $34,04628 claims |
| GSKTrelegy Ellipta | $67 | $31,08333 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $17,53022 claims |
| AbbVieSynthroid | $304 | $8,499102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Gainesville
- Christopher RecknorGainesville$9.2M
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.